CYCLOSPORINEMULSION

European patent · EP2621469 · In force

Register entry

Publication number
EP2621469
Application number
EP11767671
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 30, 2011
Published
Aug 7, 2013
Granted
Jul 20, 2016
Protection ends at the latest
Sep 29, 2031
Next annual fee due
Sep 30, 2027
IPC classes
A61K 9/107 (2006.01)
A61K 38/13 (2006.01)
Priority
US 388633 P 01.10.2010
DK 201000891 U 01.10.2010
PCT application
PCT/EP2011/067117 30.09.2011
PCT publication
WO2012/042023 05.04.2012
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. Oct 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.09.2025 → 30.09.2026

    Published in Swissreg on 01.10.2025

  3. Oct 3, 2024

    Change

    Published in Swissreg on 03.10.2024

  4. Oct 1, 2023

    Change

    Published in Swissreg on 01.10.2023

  5. Oct 1, 2022

    Change

    Published in Swissreg on 01.10.2022

  6. Jul 21, 2021

    Address changed

    Owner
    Neurovive Pharmaceutical AB, Biomedical Center D10, 221 84 Lund, Sweden → Abliva AB, Medicon Village, 223 81 Lund, Sweden

    Published in Swissreg on 21.07.2021

  7. Jul 20, 2016

    Granted

    Published in Swissreg on 20.07.2016

Parties

Holder

Abliva AB

Medicon Village, 223 81 Lund, SE

Inventor

ELMÉR, Eskil

S-224 65 Lund, SE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.